DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.
复制标题
DOI：
10.1186/1476-4598-7-81
复制
发表时间：
2008-10-23
期刊：
影响因子：
37.3
通讯作者：
Laird-Offringa, Ite A.
中科院分区：
文献类型：
--
作者：
Anglim, Paul P.;Alonzo, Todd A.;Laird-Offringa, Ite A.
肺癌是美国头号癌症杀手。这种疾病在临床上分为两种亚型，小细胞肺癌(占肺癌病例的10%-15%)和非小细胞肺癌(非小细胞肺癌)(占病例的85%-90%)。早期发现NSCLC是两种亚型中更常见、侵袭性较小的一种，具有最高的挽救生命的潜力。到目前为止，还没有能够及早发现的常规筛查方法，这是这种疾病死亡率高的关键因素。影像和细胞学筛查策略已被用于早期检测，虽然一些策略是敏感的，但没有一种策略被证明可以降低肺癌死亡率。然而，通过开发可以补充成像技术的特定分子标记，死亡率可能会降低。DNA甲基化已成为一种极具前景的生物标记物，并在多种癌症中得到积极研究。基于DNA甲基化的生物标记物的分析正在迅速发展，大量潜在的生物标记物已经被识别。在这里，我们提供了一个详细的文献回顾，重点是基于DNA甲基化的标记物开发使用原发的非小细胞肺癌组织。临床诊断的可行标记物必须能在血液、痰、支气管肺泡灌洗、甚至呼出的呼吸冷凝液等“远程介质”中检测到。我们讨论了在这种介质中检测它们的进展，以及迄今为止鉴定的分子标记面板的敏感性和特异性。最后，我们展望了通过对表观基因组的询问而可能取得的未来进展。
Lung cancer is the number one cancer killer in the United States. This disease is clinically divided into two sub-types, small cell lung cancer, (10–15% of lung cancer cases), and non-small cell lung cancer (NSCLC; 85–90% of cases). Early detection of NSCLC, which is the more common and less aggressive of the two sub-types, has the highest potential for saving lives. As yet, no routine screening method that enables early detection exists, and this is a key factor in the high mortality rate of this disease. Imaging and cytology-based screening strategies have been employed for early detection, and while some are sensitive, none have been demonstrated to reduce lung cancer mortality. However, mortality might be reduced by developing specific molecular markers that can complement imaging techniques. DNA methylation has emerged as a highly promising biomarker and is being actively studied in multiple cancers. The analysis of DNA methylation-based biomarkers is rapidly advancing, and a large number of potential biomarkers have been identified. Here we present a detailed review of the literature, focusing on DNA methylation-based markers developed using primary NSCLC tissue. Viable markers for clinical diagnosis must be detectable in 'remote media' such as blood, sputum, bronchoalveolar lavage, or even exhaled breath condensate. We discuss progress on their detection in such media and the sensitivity and specificity of the molecular marker panels identified to date. Lastly, we look to future advancements that will be made possible with the interrogation of the epigenome.
登录
查看更多内容
影响因子：
11.5
作者：
Belinsky, SA;Klinge, DM;Picchi, MA
通讯作者：
Picchi, MA
影响因子：
2
作者：
Carpagnano, GE;Resta, O;Carpagnano, F
通讯作者：
Carpagnano, F
DOI：
10.1073/pnas.95.20.11891
发表时间：
1998-09-29
影响因子：
11.1
作者：
Belinsky, SA;Nikula, KJ;Herman, JG
通讯作者：
Herman, JG
影响因子：
8
作者：
Cooper, W. N.;Dickinson, R. E.;Dallol, A.;Grigorieva, E. V.;Pavlova, T. V.;Hesson, L. B.;Bieche, I.;Broggini, M.;Maher, E. R.;Zabarovsky, E. R.;Clark, G. J.;Latif, F.
通讯作者：
Latif, F.
影响因子：
10.3
作者：
Bain, C;Feskanich, D;Colditz, GA
通讯作者：
Colditz, GA